Brazilian study says Sinovac COVID-19 jab 78% effective
State health officials in Brazil say a study has found that a vaccine candidate made by China’s Sinovac is 78% effective in protecting against COVID-19
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A vaccine candidate made by China’s Sinovac is 78% effective in protecting against COVID-19 according to results of a study announced Thursday by Brazilian state health officials seeking federal approval of the shot.
More than 12,000 health workers participated in the study, which detected 218 cases of COVID-19 — about 160 of those among people who received a placebo rather than the actual vaccine.
Turkish officials last month said that a smaller, companion study in that country of the same vaccine candidate found an efficacy rate of over 90%.
The government of Sao Paulo state, which has contracted for the vaccine, said it is asking Brazil's federal health regulators for emergency approval to begin using it. Gov. João Doria plans to start a vaccination campaign for the state's 46 million residents on Jan. 25.
The health agency said in a statement that it has not yet received full data on the study.
The researchers reported no serious side effects in the study.
The U.S. has required vaccine candidates to be tested in at least 30,000 people to determine safety and effectiveness.
The Sinovac candidate was ready for late-stage testing at a time when China had such little coronavirus spread that the company was forced to look to multiple locations abroad to amass the necessary data.
“Today is the day of hope, the day of life,” Doria said in a news conference. Brazil is nearing 200,000 deaths caused by the virus.
The Sao Paulo governor is an adversary of President Jair Bolsonaro, who has downplayed the risks of the pandemic since the beginning and has repeatedly questioned the quality of the Chinese vaccine.
A different Chinese company, SinoPharm, announced last week that its similar vaccine is about 79% effective. Both of those vaccines rely on inactivated viruses.